Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage

CompletedOBSERVATIONAL
Enrollment

1,849

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Type 2 Diabetes
Trial Locations (23)

Unknown

Research Site, Arkhangelsk

Research Site, Astrakhan

Research Site, Barnaul

Research Site, Chelyabinsk

Research Site, Izhevsk

Research Site, Kazan'

Research Site, Khemerovo

Research Site, Kirov

Research Site, Kurgan

Research Site, Moscow

Research Site, Nizhny Novgorod

Research Site, Perm

Research Site, Petrozavodsk

Research Site, Rostov-on-Don

Research Site, Samara

Research Site, Seversk

Research Site, Smolensk

Research Site, St-Peterburg

Research Site, Tomsk

Research Site, Tyumen

Research Site, Ufa

Research Site, Yaroslavl

Research Site, Yoshkar-Ola

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY